Blood pressure
A study conducted at Capital Medical University in Beijing, People's Republic of China, has found that the HFpEF-ABA score is an effective tool for identifying high-risk, undiagnosed heart failure with preserved ejection fraction (HFpEF) subgroups with elevated cardiovascular event rates. The research, which evaluated the Systolic Blood Pressure
Type 2 diabetes
Podimetrics, a Massachusetts-based company specializing in complex diabetes care, has introduced SmartMat+, a next-generation solution designed to reduce falls and monitor signs of heart failure, while continuing to help prevent diabetic foot ulcers. The innovative technology measures foot temperature, weight, and stability, enabling early risk identification and proactive intervention to
Cardiac patients
New research from the University of New Mexico College of Pharmacy indicates that the utilization rate of sodium-glucose cotransporter 2 inhibitors (SGLT2is) in patients with heart failure has improved since 2021, but these agents continue to be underprescribed despite current guideline recommendations. The study, published in the American Journal of
Cardiac patients
A recent study published in the South Valley University - International Journal of Medical Sciences has found that sodium glucose cotransporter 2 inhibitors (SGLT2i) can significantly improve heart function in patients with heart failure and pulmonary hypertension, regardless of whether they have type 2 diabetes mellitus (DM). The study, which
Cardiac patients
Researchers from the University for Health Sciences in Adana, Turkiye, have published a study investigating the effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on the development of contrast-induced nephropathy (CIN) in patients with heart failure with reduced ejection fraction (HFrEF) without diabetes mellitus (DM) undergoing elective coronary angiography (CAG) and
Cardiac patients
A recent study published in the European Journal of Internal Medicine has shed light on the efficacy of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes, and obesity. The research, conducted by a team of experts from the University of Malaga, analyzed the
Cardiac patients
Patients with elevated pulmonary artery diastolic pressure (PAD) are at a higher risk of mortality, and a new study suggests that reducing PAD early on can improve long-term mortality among Medicare beneficiaries with heart failure. Researchers at Vanderbilt University Medical Center analyzed data from over 9,500 patients who received
Associations
The American Heart Association (AHA) has issued a new scientific statement recommending the use of the Prediction of Cardiovascular Events Risk Equations (PREVENT) to personalize medical care for adults with high blood pressure. The PREVENT equations calculate the risk of total cardiovascular disease (CVD) at 10 and 30 years, including
Body weight
Women with obesity-related heart failure with preserved ejection fraction (HFpEF) experience greater weight reduction with semaglutide compared to men, but both sexes exhibit similar improvements in heart failure-related symptoms, according to a recent study published in the Journal of the American College of Cardiology. The study, which analyzed data from
Anti-obesity agents
A trial involving over 1,145 patients has found that semaglutide, a type of weight-loss jab, can help ease symptoms of heart failure, offering new hope to the hundreds of thousands of Britons affected by the condition. The analysis, presented in the Journal of the American College of Cardiology, discovered
Heart failure
Researchers have made a breakthrough discovery regarding the effects of weight-loss jabs on heart failure, a condition that affects around half a million people in Britain and is growing in Ireland. A trial found that semaglutide, a medication commonly known under the brand names Ozempic and Wegovy, helped patients lose
